Regenetech Initiates Preclinical Studies At Johns Hopkins University With Expanded Adult Stem Cells For Type 1 Diabetes Treatment

Regenetech®, Inc. announces that it has signed a Sponsored Research Agreement (SRA) with Johns Hopkins University in order to work toward a treatment for type 1 diabetes. This is in addition to the research agreements which the Company currently has in place with Texas A&M University and the University of Texas Medical Branch at Galveston. [click link for full article]

More: continued here

Filed under: Diabetes on November 18th, 2007